Novel Furazan-3-Carboxylic Acid Derivatives and Use Thereof in Treatment of Cancer

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses a new class of chemical compounds, namely furazan-3-carboxylic acid derivatives, that act as inhibitors of the transcription factor STAT5. These compounds have been shown to selectively block STAT5 signaling, which is commonly constitutively active in certain cancers, particularly in leukemia such as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The compounds are designed for use as pharmaceuticals, either alone or in combination with established kinase inhibitors, to treat cancers characterized by abnormal STAT5 activity.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of acute myeloid leukemia (AML) as a standalone therapy or in combination with other anti-cancer agents.
• Treatment of chronic myeloid leukemia (CML), especially in cases resistant to kinase inhibitors.
• Treatment of other cancers or malignancies where constitutive STAT5 signaling contributes to disease progression.
• Development of pharmaceutical compositions (tablets, injectables, etc.) using these derivatives for targeted STAT5 inhibition.
• Combination therapy regimens with kinase inhibitors (JAK, BCR-ABL, FLT3, PI3K inhibitors) to enhance efficacy and/or overcome drug resistance in cancer.
• Use as a targeted therapy in precision medicine for patients with STAT5-driven cancers.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a novel mechanism of action for cancer treatment by directly targeting and inhibiting STAT5, a key signaling molecule involved in cancer cell proliferation and survival.
• Potentially overcomes resistance mechanisms common with kinase inhibitors since STAT5 is downstream in cancer signaling pathways.
• Demonstrates selectivity for STAT5, reducing possible side effects associated with inhibition of other, related proteins like STAT3.
• May be less toxic, more efficacious, or result in fewer side effects than existing chemotherapeutics, as well as display favorable absorption and pharmacokinetic properties.
• Suitable for combination therapy with existing anti-cancer drugs, thereby offering synergistic effects and potentially improved clinical outcomes.
• Versatility in administration (oral, intravenous, other routes) and pharmaceutical formulation.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

A furazan-3-carboxylic acid derivative or pharmaceutically acceptable salt thereof for use in treatment of acute myeloid leukemia.